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Abstract 
Introduction  
We describe a screening and prevention programme primarily targeting under-served minority women at high risk of breast and/or 
ovarian cancer. Women attending this Bellevue Hospital Center (BHC) Clinic were either self-referred from a variety of special outreach 
programmes or referred internally by medical professionals caring for relatives or friends. Our objective was to delineate referral sources 
and preliminary risk-assessment findings in relation to demographic features in this population. 
Methods 
Following a detailed family and personal history intake and physical examination, each woman on her initial visit is categorized into a low 
(standard) risk, high-risk or indeterminate-risk group. Women found to be at high risk of developing breast and/or ovarian cancers are 
referred for further testing, additional screening measures, or participation in chemoprevention trials. All other women are counselled 
concerning follow-up and lifestyle issues. 
Result 
Between 2003 and 2007, 171 women for whom complete information was obtained were analysed. Thirty-four of the women were 
Caucasians (19.8%) and 137 (80.2%) were ethnically diverse minority women. Sixty-two (36.2%) were found to be at high risk with a 
median age of 42 years. The majority of the high-risk women were referred to the clinic by medical professionals (58%), most of whom 
were from within the BHC health care system. In fact, one-fourth of the referrals were women who carried a diagnosis of cancer, mostly 
arising in the breast, and who were concerned with risks to other family members. Trends in genetic testing results indicate fewer 
mutations among high-risk Asians than among other ethnicities. 
Conclusion 
Accurate risk assessments and implementation of screening and prevention measures have been challenging during the first few years 
of operation. Nevertheless, the need for providing consultation from internal referrals and the potential for genetic and psychosocial 
research in an ethnically diverse population are powerful incentives for continuing to evolve these services. 
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Introduction 
An estimated 5–10% of all breast cancer cases are attributed to 
inherited mutations in genes conferring breast cancer 
susceptibility as high as 80% life-time risk [1]. By their late 
thirties, BRCA1 mutation carriers have a 2–3% risk of 
developing ovarian cancer, and that risk rises dramatically with 
advancing age [2]. Early identification of women at risk of being 
a carrier of one such mutation is becoming increasingly 
important: a positive carrier state may lead to intensified 
screening according to recommended guidelines, or to risk 
reducing surgeries such as bilateral salpingo-oopherectomy 
(BSO) and/or mastectomy [3–5]. The timing of risk reducing 
surgery is influenced by this hereditary risk in conjunction with 
the reproductive wishes of the patient. 
Studies have shown that the prevalence of these mutations vary 
greatly between populations and ethnicities; for example while 
certain founder mutations in BRCA1 are reported to be the most 
common in Ashkenazi Jews [6–8], a single mutation in BRCA2 
can be found in the majority of high-risk families in Iceland [9]. 
Other ethnic minorities remain understudied and little is known 
about the true prevalence of the documented deleterious 
mutations and the associated lifetime risk of developing breast 
and/or ovarian cancer. The reasons for this information disparity 
are multi-factorial and have been documented in many studies: 
language barriers, cultural differences, lack of medical 
insurance and limited access to specialized care being some of 
the main explanations cited [10–13]. Geographical issues may 
contribute to the difficulties. Some minorities tend to reside in 
specific US locales, thus being under-represented in studies 
originating from other parts of the US. Being part of an 
academic centre serving a diverse population located in a major 
metropolitan area has facilitated our reaching out to under-
served minorities. From its outset in 2001, the Lynne Cohen 
High Risk Clinic targeted such minority and under-served 
populations as the main beneficiaries of its services. The 
purpose of this report is to evaluate the demographics, risk and 
referral sources of the women attending the clinic focusing on 
recent years of operation when criteria for high-risk designation 
were uniformly applied. In our particular working environment of 
a major medical facility caring for immigrant populations, one-
fourth of all the subjects were women with an established 
history of cancer, accounting for nearly half of the women that 
were subsequently identified as high risk. This experience 
points to an area of major need in caring for women with cancer 
(i.e. counselling family) as well as a likely strong consideration 
for subjects seeking cancer screening and prevention (i.e. 
breast cancer in a first-degree relative). 
 
Methods and materials 
Since 2001, 398 women were registered free of charge in the 
Lynne Cohen High Risk Clinic as part of a research project 
designed to identify women at high risk of developing breast 
and/or ovarian cancer. The resources utilized originated at the 
NYU Cancer Center and the Lynne Cohen Foundation. 
Referrals were from BHC various specialties as well as Center 
for Immigrant Health of NYU. The High Risk Clinic Staff has 
attended departmental conferences and tumour boards in 
relevant units such as Internal Medicine, Geriatrics, 
Gynecology, Gynecology-Oncology, and Medical Oncology. The 
goals of the clinic, services offered and eligibility criteria were 
presented to increase awareness and promote referrals. 
Collaboration with outreach and community programmes was 
sought out to help promote access for immigrant and minority 
women. These included the YWCA, the American Cancer 
Society Eastern Division, Latina Share, Cancer Care and the 
Women’s Outreach Network. Relatives of women found at high 
risk were also encouraged to enrol. 
Upon arrival, women go through the following procedure: 
women meet a bilingual nurse who explains the sequence of the 
visit and assists in filling out a comprehensive clinical and 
research questionnaire, available in both English and Spanish. 
Ethnic and demographic data and an expanded personal and 
family history (modified from the Gynecologic Oncology Group 
Protocol 199) are included [14]. Mammography findings and 
benign breast disease (including number of biopsies and 
results) and gynaecologic history (age of menarche, age at 
menopause, age at first and last full-term pregnancies, duration 
of lactation, use of contraceptives), any hormonal interventions 
and other past medical history with medications are recorded. 
An oncologist reviews the data at the clinical encounter, which 
is an interview and physical examination, including breast and 
pelvic exams. If applicable (women over 35 with no personal 
history of breast cancer), the National Cancer Institute’s breast 
cancer risk assessment tool is used to assess each individual 
women’s risk. This widely used and validated tool is based on a 
modified Gail model that factors in ethnicity as white/Caucasian, 
Hispanic, African-American or Asian (Rockhill et al [23]) and is 
available at http://www.cancer.gov/bcrisktool/. Based on the
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Table 1: Eligibility criteria for genetic testing 
interview and risk assessment models, the woman’s risk profile 
is discussed, with recommendations for surveillance and follow-
up. 
Since 2004, women estimated to be at an increased risk of 
breast and ovarian cancer based on personal or family history 
are referred to a dedicated genetic counsellor for a formal 
consultation in order to asses risk and determine need for 
genetic testing based on the clinic’s guidelines (Table 1). The 
information is then entered into a computerized database by a 
dedicated data manager. Monthly multidisciplinary clinic staff 
meetings are held to discuss each woman’s risk profile. Based 
on the completed questionnaire, the history and physical 
examination, and the genetic consultation if performed, women 
are stratified to one of three risk groups: low (standard), high 
and indeterminate. 
Women at low risk have no established risk factors and are 
referred for standard follow-up: mammograms every 1–2 years 
after age 40 and annual visits with a primary care physician. 
Women at high risk are those with genetic risk factors (based on 
proximal or more distant but extensively affected family 
members), clinical risk factors, or a known diagnosis on biopsy 
such as atypical hyperplasia or lobular carcinoma in situ. These 
women are followed up every six months with physical and 
pelvic examinations and are eligible to undergo genetic testing 
(Table 1). When not covered by insurance, this testing is carried 
out utilizing research funds. Positivity for BRCA1 or BRCA2 
mutation determines eligibility to certain clinical trials, as well as 
decision of referral for risk-reducing surgeries. Mammography is 
recommended to begin ten years prior to diagnosis of the 
affected relative, with follow-up mammograms every six months. 
An  indeterminate  risk is assigned if the information on family 
history or prior pathology is insufficient or requires confirmation 
prior to classifying risk level. 
 
Results 
We base our analysis on 171 new referrals seen from 2004 
through 2007, with complete data: of the 171 women, 34 were 
Caucasians (19.8%) and 137 (80.1%) were ethnically diverse 
minorities (Table 2). Assignation to high risk was made in 62 of 
the women. The percentage of high-risk designation was higher 
in Asian women, and Ashkenazi Jewish women attending the 
clinic (58.8% and 57.1%, respectively), while only 26.9% of the 
Latina women, the most heavily represented ethnic group, were 
at high risk. 
The majority of women both as a whole and in most ethnic 
groups were referred to the clinic by medical professionals, 
most from within the Bellevue health system itself (Table 3). The 
second most common referral source in minority women was 
community agencies and outreach programmes. Together these 
accounted for about a quarter of the referrals. In contrast, these 
agencies and outreach programmes comprised the most 
common referral source for Caucasian women. 
In the group referred by medical professionals, a common 
reason in the high-risk cohort was a personal history of cancer. 
This was the referral reason for 30 of the women in the high-risk 
group. The breakdown of the specific cancer types is as follows: 
23 of these 30 had a diagnosis of pre-menopausal breast 
cancer and three had ovarian cancer, two of which were serous 
papillary carcinomas and one of which is a tumour of low 
malignant potential (LMP). Three women had been diagnosed 
with other primary cancers, including stomach cancer, 
endometrial carcinoma and vulvar melanoma. Three women 
with early onset breast cancer developed bilateral disease, and 
a fourth was later diagnosed with endometrial cancer (Table 4). 
In the absence of a personal history of cancer, women were 
referred to the clinic from a routine screening test site, such as a 
mammogram or routine gynaecological examination. These
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Table 2: Patients by ethnicity, risk and age 
referrals were prompted by a family history suggestive of 
familial clustering of breast and/or ovarian cancer. It is this 
same history that motivated women to attend the clinic after 
being informed of its existence by a community agency or an 
outreach programme. 
Twenty per cent of all the women who registered in our clinic, 
and mostly among the high-risk group, belonged to ten families 
with two to five members (median 2) being screened; only two 
families were of Caucasian ethnicity. A diagnosis of breast 
cancer in first-degree relatives prompted referral in seven (six 
with one relative, and one with two relatives), whereas a 
diagnosis of ovarian cancer in a first-degree family member was 
the major impetus for referral in three families. Mother--daughter 
referrals outnumbered sister–sister referrals. 
Genetic testing for BRCA mutations has been carried out since 
2003 and more than half of these since 2007 when special 
funding was obtained from an institutional grant (see 
acknowledgement). The ethnicities of all women seen in the 
clinic from 2003 to 2007 is illustrated in Table 2. Since 2003, 88 
women were recommended for genetic testing, 44 had the test 
performed. Sixteen per cent of the women tested were African-
American (including Caribbean and West Indies origin), 27% 
Latina, 32% Asian and 3% of Eastern European Jewish origins. 
Among the ten high-risk Asian women seen during that time 
period, seven were tested and one was a carrier for the BRCA 2 
mutation, the other two had variants of unknown significance, 
BRCA 1 (V447A) and BRCA 2 (V2049M). 
 
Discussion 
Providing minority women risk-guided screening and prevention 
opportunities remains challenging. While some women may be 
highly motivated by self-perceived increased risk due to multiple 
cases of cancer in the family, many barriers exist preventing 
their enrolment into clinics and trials. Our clinic set out to 
provide specialized care at no cost thereby eliminating the 
possible lack of insurance as a major obstacle to care. 
Language barrier problems were dealt with by the presence of 
bilingual nurse and patient navigators; however, the difficulty of 
reaching the target population to inform them of the clinic’s 
services, remained an issue. Over the course of the first six 
years, the clinic staff has dedicated much of its activity to 
educational initiatives for the medical community, and to the 
formation of bonds with community and outreach programmes. 
The specific organizations approached were chosen for their 
work with particular populations and their agenda of promoting 
health education, screening and prevention. The most highly 
represented ethnic group, which also comprises the largest 
 4  www.ecancermedicalscience.com 
S
h
o
r
t
 
C
o
m
m
u
n
i
c
a
t
i
o
n
secancer 2009, 3:123 
 
 
Table 3: Source of referral to the HR clinic by ethnicity 
group of women at high risk, is the Latina. Although Ashkenazi 
Jewish and Asian women were referred less frequently to our 
clinic, the relative percentage of high-risk women was the 
highest in these groups. 
A similar approach of mapping high-risk populations and 
forming partnerships with trusted community institutions in order 
to maximize penetration to these populations was described by 
Barry and Britt, in their paper describing efforts to promote 
cervical and breast cancer screening in impoverished minority 
women [19]. While this approach may be fruitful in recruitment 
of normal risk women, its success as a recruitment tool for 
women at high risk for development of breast and/or ovarian 
cancer remains to be determined. Our efforts were directed both 
at the medical community and at the community outreach 
programmes. Most women (49.6%) were referred via medical 
professionals, 28% were referred through outreach 
organizations and programmes. The percentages were even 
more clearly divided in the group of women who were at high 
risk with 58% referred by medical professionals and 24% by 
outreach sources. A similar breakdown was observed with all 
ethnic groups, with the exception of Asian women of which 70% 
were referred by medical entities. The assistance of a dedicated 
patient navigator fluent in the common Chinese dialects likely 
resulted in the high recruitment of Asian women from the 
Bellevue medical clinics. In their paper, describing the 
establishment of under-served cancer genetics services clinic, 
Ricker et al described a similar dual approach for both in- and 
outreach [20]. It is important to understand, through models 
such as our clinic, how effective techniques of communication, 
outreach and education can lead to targeting the populations at 
risk. In this context, it is noteworthy that one-fourth of all the 
subjects were women with an established history of cancer, and 
that these accounted for nearly half of all women subsequently 
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Table 4: Primary neoplasms and breast procedures in HR women 
identified as high risk. This experience points to counselling 
families as an area of major need in caring for women with 
cancer, and conversely, to a diagnosis of breast cancer being a 
major impetus for women to seek screening and prevention 
advice for their families. The data obtainable from experience in 
clinics such as ours might lead to different paradigms for 
determining and encouraging entry into clinical trials, such as 
those that have been directed to breast cancer prevention but 
have enrolled mostly women of Caucasian origin [21–23]. 
 
Conclusion 
In conclusion, our clinic has been a valuable resource for 
internal referral of affected patients and family members of 
patients with breast cancer to discuss their risk. It also relies on 
external referrals that depend on awareness in communities 
within BHC catchment area. Classification into risk based on 
sometimes inadequate family information and challenges in 
obtaining genetic testing have been our major obstacles. On the 
other hand, the Lynne Cohen Foundation for Ovarian Cancer 
Research has sponsored research symposia activities and the 
formation of a consortium with four institutions including our 
own. This Lynne Cohen Foundation Consortium includes the 
MD Anderson Cancer Centers, the University of Alabama, the 
University of Southern California as well as our own, and the 
creation of a common registry represents an opportunity for 
subsequent collaborative research that may include prospective 
clinical trials. 
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